In contrast, for Huntington’s disease (HTT gene), also resulting from a non-haploinsufficiency disease mechanism, the use of gapmer AONs to target a SNP specific to the mutant allele emerged as a promising therapeutic strategy in vitro and in vivo.15 Here, HTT is linked to Huntington disease.